Ticker

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Wells Fargo 21 st Annual Healthcare Conference Date: Wednesday, September 9, 2026 Format: 1x1 Meetings only Citi's 2026 Biopharma Back to…

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.

Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last traded at $21.2550, with a volume of 12,107 shares. Analyst Ratings Changes Separately, Wall Street Zen lowered Spyglass Pharma from a "hold"

Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 250,000 shares of the company's stock, valued at approximately $6,478,000. Affinity Asset Advisors LLC owned about